Bactrim and Plaquenil Interaction: Safety Assessment

Key Considerations

The American Academy of Dermatology and other guidelines suggest that co-administration of Bactrim and Plaquenil is not contraindicated, but requires monitoring due to potential additive adverse effects 1, 2, 3
Both medications can be used together with appropriate monitoring and precautions, as recommended by the American Heart Association and other organizations 3

Trimethoprim/sulfamethoxazole can be used safely in patients with hepatitis B or C, suggesting its hepatic safety profile is acceptable, according to the Journal of the American Academy of Dermatology 1
Methotrexate guidelines note potential hepatotoxicity with trimethoprim but don't specifically mention hydroxychloroquine interactions, as reported by the British Journal of Dermatology 5

Trimethoprim can cause folate deficiency, which may theoretically compound with hydroxychloroquine's effects, as noted by the British Journal of Dermatology 5
Monitor for signs of bone marrow suppression, especially in elderly patients or those with renal impairment, as recommended by the British Journal of Dermatology and other organizations 5, 4

The American Geriatrics Society identifies trimethoprim-sulfamethoxazole as requiring caution in older adults, and recommends more frequent monitoring in elderly patients taking both medications 4, 5

Trimethoprim-sulfamethoxazole elimination is primarily renal, making interactions more significant in patients with reduced renal function, as reported by the British Journal of Dermatology 5
Dose adjustments may be needed based on renal function, as recommended by the American Heart Association and other organizations 3, 5

Baseline and periodic complete blood counts to monitor for hematologic effects, as recommended by the British Journal of Dermatology and other organizations 5, 4
Liver function tests to assess for hepatotoxicity, as reported by the British Journal of Dermatology 5
Electrolyte monitoring, particularly in patients also taking ACE inhibitors or ARBs, as recommended by the American Heart Association and other organizations 4
Clinical assessment for skin reactions or other adverse effects, as recommended by the British Journal of Dermatology and other organizations 5, 4

Assess the necessity of both medications and consider alternatives if appropriate, as recommended by the American Heart Association and other organizations 3, 5
Evaluate baseline renal function, hepatic function, and complete blood count, as recommended by the British Journal of Dermatology and other organizations 5, 4
Use standard dosing unless renal impairment requires adjustment, as reported by the British Journal of Dermatology 5
Monitor more frequently in high-risk patients (elderly, renal impairment), as recommended by the British Journal of Dermatology and other organizations 5, 4
Educate patient about potential side effects to report (rash, unusual bleeding/bruising, yellowing of skin/eyes), as recommended by the British Journal of Dermatology and other organizations 5, 4